Spotting fake Ozempic pens: what the visual checks miss

What did @dr.ahad.sunny actually say?

The transcript here is heavily garbled, likely due to automatic captioning struggling with what appears to be Urdu or Pashto mixed with English medical terminology. What comes through clearly is that the video compares an original Ozempic pen to a counterfeit one, referencing the pen's dial, numbers, calibration markings, and how the needle cap unscrews. The creator seems to point out physical differences in the label and the dial window as authenticity indicators.

Given the hashtags referencing KPK (Khyber Pakhtunkhwa) and Mardan in Pakistan, this video is likely aimed at a South Asian audience where counterfeit injectable medications are a documented and serious public health problem. That context matters enormously for how we evaluate the intent, and the potential harm if any of the visual guidance is wrong.

Does the science back this up?

The core premise, that counterfeit Ozempic pens exist and differ from authentic ones in observable ways, is absolutely supported by evidence. This is not a fringe concern.

The U.S. FDA issued multiple warnings in 2023 and 2024 about counterfeit semaglutide products entering supply chains globally. The WHO's Global Surveillance and Monitoring System for Substandard and Falsified Medical Products has flagged injectable GLP-1 receptor agonist counterfeits specifically. A 2023 report from the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK found counterfeit Ozempic pens with incorrect dosing mechanisms and unlabeled or mislabeled cartridges circulating in markets where demand outstripped supply.

In terms of what distinguishes a real pen: Novo Nordisk has published official guidance noting that authentic Ozempic pens have a clear dose counter window, specific label formatting with batch numbers and expiry in defined positions, and a needle cap that attaches with a defined resistance. The dial should show discrete numbered increments, not blurry or misaligned printing. These are legitimate physical verification points.

What did they get wrong (or right)?

Without a clean transcript, it is impossible to assess every specific claim with confidence. That is itself a problem. If a viewer cannot fully understand the guidance being given about a medication that involves subcutaneous injection, the video creates risk rather than reducing it.

What appears to be right: drawing attention to the dial calibration numbers and label as authenticity markers is consistent with official guidance from Novo Nordisk and regulatory bodies. The physical inspection approach is legitimate.

What is concerning: there is no mention, as far as the transcript allows us to tell, of advising viewers to obtain Ozempic only through licensed pharmacies or verified healthcare providers. Showing people how to visually inspect a pen implies they may already have a pen from an unverified source. That is a patient safety gap. Visual inspection alone is not a reliable fraud prevention method. A well-made counterfeit can pass basic visual checks. The MHRA noted that some seized counterfeits were visually convincing but contained incorrect concentrations of active ingredient, or none at all.

There is also no discussion of what to do if you suspect a counterfeit: stop use, report to a pharmacist or regulatory authority, and seek medical advice. That omission reduces the practical value of this video significantly.

What should you actually know?

Counterfeit GLP-1 medications are a real and growing threat, particularly in markets where demand is high and supply is constrained. But visual inspection of a pen is not a substitute for verified sourcing.

• Novo Nordisk maintains an official product verification page and advises patients to purchase only through licensed healthcare providers and pharmacies.
• In 2023, the FDA warned consumers about counterfeit Ozempic with lot numbers EE3703A and EY4703A that had reached patients through unauthorized sellers.
• Counterfeit injectables can contain wrong doses, wrong substances, or sterility failures. The consequences of injecting a contaminated product are not limited to ineffectiveness.
• If you are in a region with known counterfeit medication problems, such as parts of South Asia or some European grey markets, the safest approach is to obtain Ozempic exclusively through a licensed pharmacy with a valid prescription and to verify the pen's authenticity using Novo Nordisk's official resources, not a social media video.
• Semaglutide is a prescription drug for type 2 diabetes and chronic weight management. It is not interchangeable with compounded semaglutide products, which have different formulations and regulatory status.

Bottom line

The intention here is legitimate. Raising awareness about counterfeit Ozempic pens in a region where this is a known problem is a reasonable public health goal. But a visually muddled, partially intelligible video is a weak vehicle for life-or-death safety information. If @dr.ahad.sunny wants to do this well, a follow-up video with clear English or Urdu language guidance, official Novo Nordisk verification steps, and explicit instructions to report suspected counterfeits to local health authorities would be far more useful than a visual comparison that viewers may not be able to replicate reliably on their own.